The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.50 (-3.45%)
Spread: 1.00 (7.407%)
Open: 14.50
High: 14.50
Low: 14.00
Prev. Close: 14.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Berenberg cuts Anglo American and Gem Diamonds

Thu, 06th Oct 2022 10:46

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

----------

FTSE 100

----------

Bank of America raises Admiral Group price target to 2,000 (1,960) pence - 'underperform'

----------

Bank of America cuts Prudential price target to 1,360 (1,455) pence - 'buy'

----------

Bank of America cuts Aviva price target to 480 (500) pence - 'neutral'

----------

Bank of America cuts Hargreaves Lansdown price target to 1,050 (1,100) pence - 'buy'

----------

Bank of America cuts M&G price target to 222 (245) pence - 'buy'

----------

Deutsche Bank cuts M&G price target to 200 (230) pence - 'hold'

----------

Bank of America cuts Phoenix Group price target to 725 (800) pence - 'buy'

----------

HSBC raises Legal & General price target to 350 (335) pence - 'buy'

----------

Bank of America cuts Legal & General price target to 280 (315) pence - 'buy'

----------

Deutsche Bank cuts St James's Place target to 1,370 (1,420) pence - 'buy'

----------

Bank of America cuts St James's Place price target to 1,300 (1,435) pence - 'neutral'

----------

RBC raises Segro to 'outperform' (sector perform) - price target 900 (1,075) pence

----------

RBC cuts British Land price target to 330 (375) pence - 'sector perform'

----------

RBC cuts Land Securities price target to 550 (650) pence - 'sector perform'

----------

Goldman Sachs raises Standard Chartered price target to 890 (870) pence - 'buy'

----------

Goldman Sachs raises HSBC price target to 750 (705) pence - 'neutral'

----------

UBS cuts Intertek price target to 6,000 (6,500) pence - 'buy'

----------

UBS cuts RS Group price target to 1,300 (1,375) pence - 'buy'

----------

UBS cuts Experian price target to 3,200 (3,400) pence - 'buy'

----------

Goldman Sachs cuts Auto Trader Group price target to 621 (625) pence - 'neutral'

----------

HSBC cuts Auto Trader Group price target to 740 (795) pence - 'buy'

----------

Goldman Sachs cuts Tesco price target to 245 (255) pence - 'buy'

----------

Credit Suisse cuts Tesco price target to 238 (292) pence - 'neutral'

----------

Credit Suisse cuts Sainsbury price target to 184 (231) pence - 'underperform'

----------

Goldman Sachs cuts Next price target to 5,750 (7,600) pence - 'neutral'

----------

RBC raises Burberry price target to 1,800 (1,700) pence - 'sector perform'

----------

Goldman Sachs raises Burberry price target to 2,490 (2,410) pence - 'buy'

----------

Exane BNP starts Entain with 'outperform' - price target 13,500 pence

----------

Exane BNP starts Flutter with 'outperform' - price target 12,500 pence

----------

Deutsche Bank cuts Reckitt price target to 6,900 (7,200) pence - 'buy'

----------

Berenberg cuts Anglo American to 'hold' (buy) - price target 3,000 (3,200) pence

----------

Berenberg cuts Endeavour Mining price target to 2,900 (3,000) pence - 'buy'

----------

Berenberg raises Fresnillo price target to 800 (700) pence - 'hold'

----------

Berenberg cuts Rio Tinto price target to 4,000 (4,300) pence - 'sell

----------

FTSE 250

----------

Berenberg cuts Sirius Real Estate price target to 123 (150) pence - 'buy'

----------

RBC cuts Great Portland price target to 470 (485) pence - 'underperform'

----------

RBC cuts Workspace Group price target to 600 (675) pence - 'outperform'

----------

RBC cuts Derwent London price target to 2,000 (2,100) pence - 'underperform'

----------

RBC cuts Hammerson price target to 15.5 (16.5) pence - 'underperform'

----------

RBC cuts Big Yellow Group price target to 1,100 (1,200) pence - 'underperform'

----------

RBC cuts Warehouse REIT price target to 115 (120) pence - 'underperform'

----------

RBC cuts Tritax Eurobox price target to 90 (105) pence - 'outperform'

----------

RBC cuts Tritax Big Box price target to 190 (205) pence - 'outperform'

----------

RBC cuts LondonMetric Property price target to 245 (270) pence - 'outperform'

----------

Barclays cuts Computacenter price target to 2,385 (2,900) pence - 'equal weight'

----------

Barclays cuts Babcock International target to 325 (358) pence - 'equal weight'

----------

Jefferies cuts Spire Healthcare price target to 240 (251) pence - 'hold'

----------

Jefferies cuts Johnson Matthey price target to 2,300 (2,400) pence - 'buy'

----------

Numis cuts Synthomer to 'hold' ('add') - target 120 (230) pence

----------

Berenberg raises Centamin price target to 114 (112) pence - 'buy'

----------

UBS cuts Serco price target to 190 (210) pence - 'buy'

----------

Barclays cuts Renishaw price target to 3,520 (3,975) pence - 'underweight'

----------

Berenberg cuts John Wood price target to 180 (270) pence - 'buy'

----------

UBS cuts Hays price target to 160 (220) pence - 'buy'

----------

Bank of America cuts Quilter price target to 104 (115) pence - 'underperform'

----------

Bank of America cuts Direct Line price target to 185 (195) pence - 'underperform'

----------

JPMorgan cuts Close Brothers price target to 1,240 (1,370) pence - 'neutral'

----------

Bank of America cuts Ninety One price target to 215 (220) pence - 'neutral'

----------

Bank of America raises Man Group price target to 305 (300) pence - 'buy'

----------

Bank of America cuts Jupiter Fund price target to 85 (115) pence - 'underperform'

----------

Bank of America cuts Ashmore Group price target to 175 (185) pence - 'underperform'

----------

Deutsche Bank cuts abrdn price target to 125 (135) pence - 'sell'

----------

Credit Suisse cuts Moneysupermarket target to 202 (208) pence - 'neutral'

----------

SMALL CAP

----------

UBS cuts Just Eat Takeaway price target to 2,200 (2,400) pence - 'buy'

----------

Berenberg raises Yellow Cake price target to 600 (500) pence - 'buy'

----------

Berenberg raises Yamana Gold price target to 660 (640) pence - 'buy'

----------

Berenberg cuts Resolute Mining price target to 48 (49) pence - 'buy'

----------

Berenberg cuts Tharisa price target to 250 (270) pence - 'buy'

----------

Berenberg raises Sovereign Metals price target to 84 (75) pence - 'buy'

----------

Berenberg cuts Jubilee Metals price target to 19 (20) pence - 'buy'

----------

Berenberg cuts Hochschild Mining price target to 90 (100) pence - 'hold'

----------

Berenberg cuts Griffin Mining price target to 140 (160) pence - 'buy'

----------

Berenberg cuts Central Asia Metals price target to 280 (300) pence - 'buy'

----------

Berenberg raises BHP Group price target to 2,300 (2,100) pence - 'hold'

----------

Berenberg cuts Atalaya Mining price target to 310 (370) pence - 'buy'

----------

Berenberg cuts Anglo Pacific Group price target to 330 (390) pence - 'buy'

----------

Berenberg raises Petra Diamonds to 'buy' (hold) - price target 200 (130) pence

----------

Berenberg cuts Gem Diamonds to 'hold' (buy) - price target 40 (60) pence

----------

RBC raises Empiric Student Property target to 90 (84) pence - 'sector perform'

----------

Jefferies cuts Angle price target to 170 (200) pence - 'buy'

----------

Bank of America cuts Old Mutual price target to 68.50 (76) pence - 'buy'

----------

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.